In June 2018, Ergul and colleagues published the results of a single-center, randomized controlled trial in the European Journal of Pediatrics titled “Using a high-flow nasal cannula provides superior results to OxyMask delivery in moderate to severe bronchiolitis: a randomized controlled study.”
Vapotherm’s Hi-VNI® Technology is a tool for treating respiratory distress in hospital settings. The views and ideas presented in this video are solely those of the speaker, and the content is not intended to serve as medical advice. Vapotherm does not practice medicine or provide medical services.
In March 2018, Kline and colleagues published a literature review in Clinical Pediatric Emergency Medicine titled “High Flow Nasal Cannula Therapy in Bronchiolitis Across the Emergency Department and Acute Care Floor.” Given the increased prevalence of High Flow Nasal Cannula (HFNC) use on bronchiolitis patients, the authors set out to review existing studies on the efficacy of this modality as well as its use in acute care settings.
In May 2017, Sochet and colleagues published the results of a prospective, single-center, observational cohort study in the journal Hospital Pediatrics titled “Oral Nutrition in Children With Bronchiolitis on High-Flow Nasal Cannula Is Well Tolerated.” The study looked at 132 children (1 month – 2 years) who had been diagnosed with bronchiolitis…
In August 2017, Collins and colleagues published the results of a decision analysis simulation model in Hospital Pediatrics titled “High-Flow Nasal Cannula in Bronchiolitis: Modeling the Economic Effects of a Ward-Based Protocol.” The analysis was based on data from Seattle Children’s Hospital and included 1,432 patients under the age of 2 who had a diagnosis of bronchiolitis.
Although pediatricians have often used albuterol to manage bronchiolitis in infants and children, the 2014 Clinical Practice Guideline on Bronchiolitis released by the American Academy of Pediatrics strongly recommend against this use. The document includes direction on diagnosis and risk factor assessment, but states that once a diagnosis of bronchiolitis is made, clinicians should not administer albuterol.
Asthma is one of the most pervasive chronic pediatric diseases, accounting for about 1.6 million emergency department (ED) visits annually and showing an upward trend. Emergency clinicians have been suspecting that High Flow Nasal Cannula (HFNC) could be a safe and effective tool in the treatment of children with asthma, but research on the subject has been sparse.
In August 2017, Angoulvant and colleagues published the results of a randomized controlled trial in JAMA Pediatrics titled “Effect of Nebulized Hypertonic Saline Treatment in Emergency Departments on the Hospitalization Rate for Acute Bronchiolitis”. The trial included 777 infants presenting in the Emergency Department with a first episode of acute bronchiolitis, but who were otherwise healthy.
The results of the prospective, multi-center randomized controlled trial were published by Franklin and colleagues in March 2018 in New England Journal of Medicine titled A Randomized Trial of High-Flow Oxygen Therapy in Infants with Bronchiolitis. The trial found among infants with bronchiolitis, those treated with high flow nasal cannula (HFNC) had significantly lower rates of escalation of care due to treatment failure than those treated with standard Oxygen therapy.